Core Insights - Baiyi Yuan Bio, a company in the regenerative medicine sector, recently secured several tens of millions of RMB in financing, exclusively invested by listed company Kangzhe Pharmaceutical, aimed at new product development, market expansion, and production line upgrades [1] - The company focuses on developing and producing novel biomedical materials, particularly extracellular matrix (ECM) products for tissue repair, wound healing, and regenerative medical aesthetics [1][3] - Baiyi Yuan Bio has established two major technology platforms: SIS-ECM (porcine small intestine submucosa ECM) and AAM-ECM (decellularized adipose matrix), and has developed core products such as the absorbable biological membrane and dura mater biological patch [3][4] Company Overview - Founded in 2011, Baiyi Yuan Bio has built a research and development center and a GMP industrialization base in Shanghai, and received high-tech enterprise certification in 2019 [1] - The company’s SIS-ECM is derived from porcine small intestine submucosa, known for its excellent biocompatibility and rich collagen and growth factors, which play a crucial role in tissue repair and regeneration [1][3] Product Applications - The absorbable biological membrane is primarily used in guided bone regeneration (GBR) for dental implants, providing an ideal microenvironment for bone regeneration and reducing postoperative complications [4] - The dura mater biological patch is designed for neurosurgery, aimed at repairing and reconstructing the dura mater while lowering the risk of postoperative infections [4] - Both products have entered the commercialization phase and are expected to generate over 10 million RMB in revenue in their first full sales year in 2024 [4] Market Potential - The application of ECM materials in the aesthetic medicine sector is a recent research hotspot, with a shift towards regenerative approaches that utilize biomedical engineering to repair and regenerate damaged tissues [5] - Baiyi Yuan Bio is also developing ECM materials for aesthetic applications, with plans to submit product registration applications for SIS-ECM filling products by the end of the year [5][6] - While there are existing applications of ECM materials in aesthetic medicine overseas, the widespread adoption in mainland China may still face regulatory hurdles [6]